Item 7.01 Regulation FD Disclosure.

On January 13, 2021, Eagle Pharmaceuticals, Inc., or the Company, will present the attached presentation of the Company's products and product candidates at the 39th Annual J.P. Morgan Healthcare Conference, taking place virtually on January 11-14, 2021.

A copy of the above-referenced presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to Item 7.01 of this current report, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of the Company's filings under the Securities Act of 1933, as amended or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing. The furnishing of the information in this Current Report on Form 8-K is not intended to, and does not, constitute a determination or admission by the Company that the information in this Current Report on Form 8-K is material or complete, or that investors should consider this information before making an investment decision with respect to any security of the Company.

Item 9.01 Financial Statements and Exhibits.






(d) Exhibits




Exhibit No.                                   Description
   99.1         Presentation of the Company dated January 2021
    104       Cover Page Interactive Data File (embedded within the Inline XBRL document)

© Edgar Online, source Glimpses